Skip to content
Sunday, September 8, 2024
Wall Street Insider
Deliver critical advise to busy investors
Search
Search
News
About Us
Services
Institutional Research
Portfolio Analysis
#1 Stock Pick
Subscriptions
Contact Us
CLIENT LOGIN
Home
News
Regeneron accused of ‘fraudulent’ drug-pricing reporting for eye drug Eylea
News
Regeneron accused of ‘fraudulent’ drug-pricing reporting for eye drug Eylea
April 11, 2024
Arthur Bleemer
The Department of Justice on Wednesday accused drug maker Regeneron Pharmaceuticals Inc. of fraudulent practices related the pricing of its blockbuster vision-impairment drug Eylea, boosting its sales in the process.
Read more from source
Post navigation
I invested half of my son’s inheritance with a 13.5% return. A major broker underperformed the S&P 500 with the rest. Should I take over all his assets?
Rent the Runway sees ‘milestone’ 2024 and breakeven cash flow, as stock soars